No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for Immix Biopharma, Inc. (IMMX) stock was $9.59 as of Oct 6, 2026, 10:30 AM EDT, down 5.33% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +388.0% · 3-year avg +39.3%/yr
Immix Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to creating a range of tissue-specific therapies.
Biotechnology · Los Angeles, CA
Next Earnings Date
Nov 6, 2026
31 days away
EPS Estimate
-0.19
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.18
vs Estimate
$-0.18
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1IMMX | $521.71M | $9.59 | -5.33% | +388.03% | N/A | N/A | N/A |
| 2ALT | $519.25M | $2.67 | N/A | -31.59% | -25.30% | N/A | vs IMMX |
| 3MASS | $513.46M | $12.52 | -2.23% | +40.89% | -17.66% | N/A | vs IMMX |
| 4CBIO | $530.04M | $14.27 | +2.37% | +18.84% | -24.40% | -22.94% | vs IMMX |
| 5MNPR | $510.67M | $76.23 | -2.63% | -21.14% | +27.38% | N/A | vs IMMX |
| 6DCTH | $534.57M | $15.48 | -2.43% | +42.73% | +10.90% | N/A | vs IMMX |
forward FY estimate
N/A
$0.00
vs Estimate
$0.00
Consensus Rating
Based on 8 analysts
Average Price Target
$24.30
+153.4% upside
Low
$17.40
Current
$9.59
High
$30.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.20 | $-0.19 | $-0.17 | 5 |
| Quarter ending Dec 2026 | $-0.19 | $-0.19 | $-0.19 | 4 |
| Quarter ending Mar 2027 | $-0.23 | $-0.23 | $-0.23 | 1 |
| Quarter ending Jun 2027 | $-0.27 | $-0.27 | $-0.27 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.74 | $-0.71 | $-0.69 | 6 |
| FY 2027 | $-1.84 | $-0.85 | $-0.29 | 6 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Dec 2026 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Mar 2027 | $0.00 | $0.00 | $0.00 | 0 |
| Quarter ending Jun 2027 | $0.00 | $0.00 | $0.00 | 0 |
Annual
| Period | Low |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $5.03M | $12.14M | $20.98M | 5 |
| FY 2027 | $3.76M | $26.40M | $49.05M | 4 |
